1. |
Martini N, Flehinger BJ, Zaman MB, et al. Prospective study of 445 lung carcinomas with mediastinal lymph node metastases. J Thorac Cardiovasc Surg, 1980 , 80 (3):390-399.
|
2. |
Cybulsky IJ, Lanza LA, Ryan MB, et al. Prognostic significance of computed tomography in resected N2 lung cancer. Ann Thorac Surg, 1992 , 54 (3):533-537.
|
3. |
Pearson FG, DeLarue NC, Ilves R, et al. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg, 1982, 83 (1):1-11.
|
4. |
Perez CA, Pajak TF, Rubin P, et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinomaof the lung treated with definitive radiotherapy. Report by the RadiationTherapy Oncology Group. Cancer, 1987, 59 (11):1874-1881.
|
5. |
Vansteenkiste J, De Leyn P, Deneffe G, et al. Present status of induction treatment in stage ⅢA-N2 non-small cell lung cancer:a review.Eur J Cardiothorac Surg, 1998, 13 (1):1-12.
|
6. |
Pass HI, Pogrebniak HW, Steinberg SM, et al. Randomized trial of neoadjuvant therapy for lung cancer:interim analysis. Ann Thorac Surg, 1992, 53 (6):992-998.
|
7. |
Rosell R, Gómez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med, 1994, 330 (3):153-158.
|
8. |
Roth JA, Fossella F, Komaki R, et al. A randomized trial comparingperioperative chemotherapy and surgery with surgery alone in resectablestage ⅢA non-small-cell lung cancer. J Natl Cancer Inst, 1994, 86 (9):673-680.
|
9. |
Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage ⅢA non-small-cell lung cancer. Lung Cancer, 1998, 21 (1):1-6.
|
10. |
Depierre A, Milleron B, Moro D, et al. Phase Ⅲ trial of neo-adjuvantchemotherapy in resectable stage Ⅰ (except T1N0), II and Ⅲa non-smallcell lung cancer:The French experience. J Clin Oncol, 2002 , 20 (1):247-253.
|
11. |
Nagai K, Tsuchiya R, Mori T, et al. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage ⅢA N2 non-small cell lung cancer (JCOG 9209) . J Thorac Cardiovasc Surg, 2003, 125 (2):254-260.
|
12. |
Pisters KM, Vallières E, Crowley JJ, et al. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer:Southwest Oncology Group Trial S9900, an intergroup, randomized, phase Ⅲ trial. J Clin Oncol, 2010, 28 (11):1843-1849.
|
13. |
Scagliotti GV, Pastorino U, Vansteenkiste JF, et al. Randomized phase Ⅲ study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages ⅠB to ⅢA non-small-cell lung cancer. J ClinOncol, 2012 , 30 (2):172-178.
|
14. |
Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage Ⅲ non-small-cell lung cancer:seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst, 1996, 88 (17):1210-1215.
|
15. |
Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer:first analysis of a randomized trial in 353 patients. J Natl Cancer Inst, 1991, 83 (6):417-423.
|
16. |
Sause W, Kolesar P, Taylor SIV, et al. Final results of phase Ⅲtrial in regionally advanced unresectable non-small cell lung cancer:Radiation therapy oncology group, eastern cooperative oncology group,and southwest oncology group. Chest, 2000, 117 (2):358-364.
|
17. |
Johnstone DW, Byhardt RW, Ettinger D, et al. Phase Ⅲ study comp-aring chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung Cancer with spread to mediastinal lymph nodes (N2);final report of RTOG 89-01. Radiation therapy oncology group. Int J Radiat Oncol Biol Phys, 2002, 54 (2):365-369.
|
18. |
Taylor NA, Liao ZX, Cox JD, et al. Equivalent outcome of patients with clinical stage ⅢA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection. Int J Radiat Oncol Biol Phys, 2004, 58 (1):204-212.
|
19. |
Van Meerbeeck JP, Van Schil PE, Senan S. Reply:randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage ⅢA-N2 non-small cell lung cancer. J Natl Cancer Inst,2007, 2 (12):1138-1139.
|
20. |
Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage Ⅲ non-small-cell lung cancer:a phase Ⅲ randomised controlled trial. Lancet, 2009, 374 (9687):379-386.
|
21. |
Bosch-Barrera J, García-Franco C, Guillén-Grima F, et al. The multimodal management of locally advanced N2 non-small cell lung cancer:is there a role for surgical resection ? A single institution's experience. Clin Transl Oncol, 2012, 14 (11):835-841.
|
22. |
Ratto GB, Costa R, Maineri P, et al. Is there a subset of patients with preoperatively diagnosed N2 non-small cell lung cancer who might benefit from surgical resection ? J Thorac Cardiovasc Surg, 2009 , 138 (4):849-858.
|
23. |
Funakoshi Y, Takeuchi Y, Kusumoto H, et al. Which subgroup of patients with pathologic N2 non-small cell lung cancer benefit from surgery ? J Cancer Res Clin Oncol, 2012, 138 (6):1027-1033.
|
24. |
Sakao Y, Okumura S, Mun M, et al. Prognostic heterogeneity in multilevel N2 non-small cell lung cancer patients:importance of lymphadenopathy and occult intrapulmonary metastases. Ann Thorac Surg, 2010, 89 (4):1060-1063.
|
25. |
Lorent N, De Leyn P, Lievens Y, et al. Long-term survival of surgically staged ⅢA-N2 non-small-cell lung cancer treated with surgical combined modality approach:analysis of a 7-year prospective experience. Ann Oncol, 2004, 15 (11):1645-1653.
|
26. |
Stefani A, Alifano M, Bobbio A, et al. Which patients should be operated on after induction chemotherapy for N2 non-small cell lung cancer ? Analysis of a 7-year experience in 175 patients. J Thorac Cardiovasc Surg, 2010, 140 (2):356-363.
|
27. |
Lococo F, Cesario A, Margaritora S, et al. Long-term results in patients with pathological complete response after induction radiochemotherapy followed by surgery for locally advanced non-small-celllung cancer. Eur J Cardiothorac Surg, 2013, 43 (3):e71-e81.
|
28. |
Bueno R, Richards WG, Swanson SJ, et al. Nodal stage after induc-tion therapy for stage ⅢA lung cancer determines patient survival. AnnThorac Surg, 2000, 70 (6):1826-1831.
|
29. |
Decaluwé H, De Leyn P, Vansteenkiste J, et al. Surgical multimodality treatment for baseline resectable stage ⅢA-N2 non-small cell lungcancer. Degree of mediastinal lymph node involvement and impact on survival. Eur J Cardiothorac Surg, 2009 , 36 (3):433-439.
|
30. |
Sawabata N, Keller SM, Matsumura A, et al. The impact of residualmulti-level N2 disease after induction therapy for non-small cell lung cancer. Lung Cancer, 2003, 42 (1):69-77.
|
31. |
Steger V, Walker T, Mustafi M, et al. Surgery on unfavourable persistent N2/N3 non-small-cell lung cancer after trimodal therapy:do the results justify the risk ? Interact Cardiovasc Thorac Surg, 2012 , 15 (6):948-953.
|
32. |
Katakami N, Tada H, Mitsudomi T, et al. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapybefore surgery in patients with pathologically confirmed N2 stage ⅢA nonsmall cell lung cancer (WJTOG9903) . Cancer, 2012, 118 (24):6126-6135.
|
33. |
Koshy M, Fedewa SA, Malik R, et al. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage ⅢA (N2)non-small-cell lung cancer. J Thorac Oncol, 2013, 8 (7):915-922.
|
34. |
National Institute for Health and Clinical Excellence (NICE). The Diagnosis and Treatment of Lung Cancer (Update):Full Guideline. London:National Collaborating Centre for Cancer, 2011. 59-63.
|
35. |
Lim E, Baldwin D, Beckles M, et al. Guidelines on the radical management of patients with lung cancer:British Thoracic Society and the Society for Cardiothoracic surgery in Great Britain and Ireland.Thorax , 2010, 65 (Suppl Ⅲ):1-27.
|
36. |
Ramnath N, Dilling TJ, Harris LJ, et al. Treatment of stage Ⅲ non-small cell lung cancer:Diagnosis and management of lung cancer, 3rd ed. American college of chest physicians evidence-based clinical practice guidelines. Chest, 2013, 143 (5 Suppl):314S-340S.
|